Abstract: This invention is related to a pharmaceutical composition made up by the synergic combination of a nonsteroidal anti-inflammatory analgesic such as Aceclofenac or its pharmaceutically acceptable salts and an anti-inflammatory steroid agent such as the active ingredient Betamethasone or its pharmaceutically acceptable phosphate or dipropionate salts, which are formulated in a single dosing unit for topical, intramuscular or intravenous administration, which is indicated for the treatment of the localized pain of rheumatic diseases.

Abstract: The present invention is related to a novel formulation comprising active pharmaceutical ingredients, optionally in combination with other active pharmaceutical ingredients which are capable of inhibiting replication of the virus belonging to the family Coronaviridae. The present invention formulation includes Andrographis paniculata, PVP K30 and Acrylic polymer. The present invention further relates to different pharmaceutical formulations that have different modes of application.

Abstract: Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic.

Abstract: An injury contact prevention band includes an injury cover portion and a fastening portion. The injury cover portion covers a part of a body including an injury. The fastening portion fastens the injury cover portion to the body. A plurality of injury opening holes cutting through a thickness of the injury cover portion to expose the injury. The fastening portion includes a first fastening member, a second fastening member, and a connecting member. The first fastening member extends from an end of the injury cover portion and has flexibility. The second fastening member extends from an other end of the injury cover portion and has flexibility. The connecting member detachably connects an end of the first fastening member and an end of the second fastening member to each other. The plurality of injury opening holes is arranged along at least one direction.

Abstract: By the ingestion of dosage forms containing sparingly water-soluble drug particles, it is not possible to deliver drug into the blood stream at high rates, because the drug dissolution rate, and the absorption rate, are limited by solubility. Herein, therefore, dosage forms comprising a slender, three-dimensional structural framework of sparingly-soluble drug dissolved in an excipient matrix comprising at least a water-soluble polymer carrier and an amphiphilic polymer are disclosed. Upon immersion in a physiological fluid, said fluid wets the structural framework, interdiffuses with it, and the amphiphilic polymer self-assembles as micelles, thereby enhancing drug solubility. Concomitantly, the framework erodes and rapidly releases drug molecules, thus enhancing drug concentration in the fluid and the drug delivery rate into the blood stream.

Abstract: An active composition delivery system having a water-soluble top layer, a water-soluble bottom layer, and an active composition disposed therebetween. The water-soluble top and bottom layers are joined together to form a pouch sized and shaped to hold an amount of an active composition. The active composition delivery system further includes a plurality of water-soluble joints, joining the top and bottom water-soluble layers.

Abstract: Methods, systems, and apparatuses are described herein for improving computer authentication processes by generating authentication questions based on the location of a user. Transaction data indicating a plurality of transactions associated with a user account may be received. Location data indicating a plurality of locations of a user device might be received. At least a subset of the plurality of transactions may be tagged, based on the location data, with an indication that a user was present for a respective transaction. For example, a location of a merchant might be compared to a user device location indicated by the location data. A plurality of authentication questions might be generated based on the subset of the plurality of transactions. Access to the user account might be provided based on responses to the plurality of authentication questions.

Abstract: The invention provides a composition comprising a seaweed extract in an amount of 50-90% by weight, a water-soluble cellulose derivative in an amount of 10-40% by weight and water in an amount of 1-20% by weight, of the total weight of the composition. The invention also provides products, including packaging material, formed from the composition, a method of dissolving, composting and biodegrading the composition or the products, a method of producing the composition and the products, and a method of re-working the composition.

Abstract: Medical dressings including stiffening systems fixedly attached to backing layers are described herein along with methods of using the medical dressings. The stiffening system is fixedly secured to the backing to limit flexing and stretching of the backing layer. Typically, the medical dressing and stiffening system is applied over a medical device that is secured to skin. The stiffening system covers some of the medical device and also extends beyond the medical device. The stiffening system stabilizes the medical device over the skin.

Abstract: A transdermal patch contains a water-based solution containing electrolytes, vitamins, and at least one permeation enhancer. The water-based solution also acts as an adhesive matrix which binds the patch together. The solution is transferred to the body via an embossed release liner. In use, the permeation of electrolytes into the bloodstream improves the body's ability to manage hydration. The permeation enhancer increases the porosity of the skin in contact with the transdermal patch to make possible the permeation of the solution into the body. Critical proportions of solvent, solutes, and permeation enhancers are disclosed which have been found to make permeation of otherwise non-absorbable ingredients possible.

Abstract: Cardiac tissue-on-a-chip platforms aimed at mimicking human cardiac tissue structures, are valuable tools to model, and serve as preclinical platforms for drug testing or therapies for cardiac repair. We have developed three types of electrospun scaffolds including furfuryl gelatin (f-gelatin) alone, with polycaprolactone (PCL) in the ratio of f-gelatin and PCL (1:1), and coaxial scaffolds with PCL (core) and f-gelatin (sheath). Scaffolds were developed through single nozzle electrospinning and coaxial electrospinning, respectively, to serve as scaffolds for cardiac tissue-on-a-chip platforms.

Abstract: Provided herein is a pressure sensitive adhesive (PSA) comprising two different acrylate polymers and a metal chelating agent to produce the PSA. The PSAs produced according to the methods described herein can be used under a broad range of working temperatures, i.e., from ?99° C. to 40° C., e.g., ?40° C. to 37° C. These PSAs demonstrate optimal tack and cohesiveness and/or resistance to warm water bath, when affixed to substrates.

Abstract: The present invention relates to a pharmaceutical dosage form for application to a mucous membrane, in particular to a buccal, intestinal, rectal or vaginal mucous membrane, comprising at least one sheet like, in particular film shaped, foil shaped or wafer shaped preparation comprising the active pharmaceutical ingredient, a release mechanism, and a trigger mechanism, wherein the trigger mechanism is adapted to trigger, at a predetermined site of action, in particular of the gastrointestinal tract, of the rectum or of the vagina, the release of the sheet like preparation by the release mechanism.

Abstract: The formation of scars at a wound site is reduced by contacting the wound site with an effective dose of an inhibitor of focal adhesion kinase (FAK) formulated in a pullulan hydrogel The release profile of the FAK inhibitor can be adjusted according to the nature of the wound, e.g., excisional wounds, burn wounds, etc.

Abstract: The systems and methods described herein can identify meaningful relationships between variables, such as particular investments or general asset classes. Unlike conventional correlation analysis, these systems and methods provide an improved technique of co-movement analysis that implements a threshold to eliminate data “noise” and then discretizes the remaining observations to normalize any outliers. Such co-movement analysis has numerous advantages over known techniques for characterizing relationships between variables.

Abstract: A drug-loaded nanofiber membrane includes a first fiber, a second fiber, and a drug. The drug is dispersed into the first fiber. The first fiber includes poly(lactic-co-glycolic acid) copolymer (PLGA copolymer), and the second fiber includes poly(p-dioxanone) (PDO).

Abstract: Thermally stable absorbable fiber populations, i.e. fiber populations that do not undergo thermally induced crystallization, can be intermixed with thermally unstable fibers to yield a stabilizing effect without altering morphological properties of a fiber system. Via this, one may minimize thermally induced shrinkage and maintain physical properties of electrospun materials in the as-formed state.

Abstract: A composition that can solvate biofilms and disrupt bacterial cell walls acts to both kill the bacteria by cell lysis and remove the biofilm. This solvent-containing composition is effective against a broad spectrum of microbes and can be used on a variety of surfaces, both living and inanimate. The polarity of the solvent component of the composition is lower than that of pure water so that the composition exhibits increased efficacy in solvating the macromolecular matrix of a biofilm and in penetrating bacterial cell walls.

Abstract: A biodegradable adhesive for use in at least one chosen from glue lap, case and carton seal, slower speed carton seal and bookbinding, the biodegradable adhesive including at least one chosen from: % (Parts) Water: 35-50 Defoamer: .3-.8 Gelatin: 25-35 Preservative: .2-.5 Glycerin: ?7-15 Epsom Salt: 10-20 Vanilla Extract: <1 Total Parts: 100%? and Water: 33-45 Defoamer: .3-.8 Gelatin: 35-45 Glycerin: 15-27 Preservative: .2-.5 Vanilla Extract: <1 Total: 100%.

Abstract: The invention relates to a printed hemostatic product having at least three-dimensions and being made of a stack of layers deposited on one another from a first external layer up to a second external layer, wherein adjacent layers of the stack of layers are joined together, and wherein at least one layer of the stack of layers has at least one portion made from an hemostatic flowable with a composition comprising: non-cross-linked collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen; and—at least one monosaccharide. The invention also relates to a method for forming such an hemostatic product with a three-dimensional additive printer, and the use of an hemostatic flowable as a printing ink in such a three-dimensional additive printer.

Abstract: The present disclosure relates to a manufacturing process of a silicone glove, the silicon glove is divided into a liner, a glove blank and a silicon layer from the inside to the outside, and liquid silicon is sprayed on a surface of the glove blank for once; when spraying the liquid silicon, the glove blank also rotates around its axis while horizontally moving on an assembly line; during spraying, a liquid silicon outflow channel at least includes a finger gap spraying port and a tiger mouth spraying port that are arranged fixedly; an arranging length of the finger gap spraying port is greater than or equal to a length of a finger area of the glove blank; an arranging length of the tiger mouth spraying port is greater than or equal to a length of a tiger mouth area of the glove blank.

Abstract: A monitor device (4) for a wound dressing system the device comprising a processor; a memory; a first interface connected to the processor and the memory, configured for collecting wound data from a wound dressing (2), the wound data comprising wound data from different sensor points of the wound dressing; and a second interface. The processor configured to: obtain parameter data based on the wound data; and determine an operating state of the wound dressing based on the parameter data, wherein the operating state is indicative of a degree of wetting of the wound dressing.

Abstract: There is disclosed systems and methods for non-invasive delivery of an agent to biological tissues. Delivery of the agent to the tissues can be by one or more modalities. In some embodiments the systems and methods use agent carrier body including a tissue contacting surface for non-invasively engaging tissues under treatment. The tissue contacting surface can be at least partly defined by a plurality of protrusions that are in fluid communication with one or more reservoirs forming part of the agent carrier body. The protrusions may extend outward from an inside of a void and terminate at said tissue contacting surface.

Abstract: Described are systems and methods for in vivo multi-material bioprinting. The in vivo multi-material bioprinting can be used to fabricate biomedical constructs within a patient minimally invasively. The systems and methods can utilize a multi-material bioprinter, which includes a biocompatible portion. The biocompatible portion can include a single printhead for in vivo bioprinting. The single printhead can include a plurality of outlets, each linked to one of a plurality of reservoirs. Each of the plurality of reservoirs can each house a different bioink for bioprinting. Each of the plurality of outlets can be activated to release a respective bioink.

Abstract: It provides a device for applying nanofibers and/or microfibers onto a substrate (S). It also provides a system comprising a plurality of such devices which are controlled to operate independently. The system allows for depositing of a gradient material in various parameters including material thickness, fiber pore size, fiber diameter, fiber content and the like. It also relates to a method for applying nanofibers and/or microfibers onto a substrate (S).

Abstract: Fibrous structures having a surface pattern of a continuous knuckle region and a plurality of discrete pillow regions such that the fibrous structures exhibit improved lotion transfer compared to known fibrous structures and better sheet control during the making of such fibrous structures are provided.

Abstract: Provided is a method of preparing an ECM material and the product of the method. The method comprises processing the ECM material with a reactive oxygen species or a reactive nitrogen species. Also provided are methods of use of the product.

Abstract: There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil.

Abstract: The present invention is based on the surprising finding of the property of promoting myelination of activators of histone deacetylase (HDAC) 1 and 2. In particular, such activators have the capacity of accelerating and increasing remyelination after lesions to the myelin of nerve cells of the peripheral and central nervous systems. The present inventor found that HDAC2 deacetylates eEF1A1 and thereby prevents the latter from removing outside the nucleus key inducers of myelin genes transcription. The HDAC1/2 activators are useful in the treatment of diseases associated with demyelination, such as Multiple Sclerosis.

Abstract: A dosage delivery film composition containing a botanical drug substance formable into a bioerodible dosage delivery film, the dosage delivery film composition including: (i) one or more of: a polymer, a plasticizer, a defoamer, or an antioxidant; (ii) a cannabinoid-cyclodextrin-terpene complex or a cannabinoid-terpene-surfactant micelle, and (iii) optionally, one or more of: a taste mask, a vasodilator, or a lipophilic vehicle to transport the botanical drug substance across the mucous membrane.

Abstract: Pharmaceutical compositions having enhanced active component permeation properties are described.

Abstract: Methods are described for treating systemic fungal and mycobacterial infections by treatment to enhances a Th1 response, reduces a Th2 response, or the combination thereof. Agents that antagonize the IL-4, the IL-13 receptor, or the combination thereof achieve the desired results.

Abstract: The present disclosure relates to the transdermal administration of cannabidiol (CBD) for the reduction of seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE).

Abstract: The present specification discloses compositions, articles of manufacture, containers or kits comprising such compositions, and methods and uses to control a causal agent of a plant disease, increasing plant growth and/or food production and/or improving performance of an irrigation system(s).

Abstract: A system for providing a force to a desired area on a curved body part of a person includes a dressing assembly shaped and configured to be placed on the desired area of the person, a releaseable circumferential member surrounding the curved body part that holds the dressing assembly against the desired area, a sealing subsystem for providing a fluid seal over the dressing assembly and the person's skin, and a reduced-pressure subsystem for providing a reduced pressure to the dressing assembly. When reduced pressure is supplied, the system generates the force against the desired area on the curved body part.

Abstract: Provided arm biocompatible polymer compositions, and methods of printing such polymer compositions using a fused deposition modelling printer to form a solid scaffold. In particular, the disclosed compositions may include a thermoresponsive polymer, and the printed scaffold may be used as a sacrificial template providing a three-dimensional vascular structure upon temperature-dependent disintegration. The present compositions and methods may be particularly useful for engineering thick tissues.

Abstract: The present invention relates to improved epicutaneous administration methods for vaccination of a subject. In particular, the present invention discloses the use of an antigen for epicutaneous immunization, wherein the antigen is administered by epicutaneous application with a skin patch device in combination with an epidermal skin treatment.

Abstract: Provided is a method by which a nucleic acid sample can be collected from a subject minimally invasively. A method for preparing a nucleic acid derived from a skin cell of a subject, comprising isolating the nucleic acid from skin surface lipids collected from the subject.

Abstract: The present invention is directed to a process for manufacturing a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and release liner. More specifically, the invention is directed to a process of preparing an adhesive layer, wherein the adhesive layer is comprised of polyisobutylene and an active pharmaceutical ingredient.

Abstract: The present disclosure provides a patch preparation having features that prevent accidental use. In some embodiments, a patch preparation containing a plaster on a support, wherein the plaster comprises a solvent that is a combination of ethyl acetate and n-heptane. The patch preparation can lose its adhesion after the plaster is exposed to air and at least some of the solvent has evaporated, or if the patch is removed from the skin. This feature prevent the used patch from being applied to the skin again, and can prevent accidental use. A method of forming a patch preparation is also disclosed.

Abstract: Systems, apparatuses, and methods for providing negative pressure to a tissue site are disclosed. Illustrative embodiments may include an apparatus or system for delivering negative-pressure to a tissue site, which can be used in conjunction with low-profile distribution components for wound therapy. Such apparatus may include a low-profile dressing interface or connector comprising at least two fluid pathways fluidly coupled to a recessed space of the connector, one for providing negative pressure to a tissue interface or manifold and the other for sensing the negative pressure within the recessed space adjacent the tissue interface. In some embodiments, a pressure-offloading layer may be disposed against at least one of the fluid pathways.

Abstract: An antimicrobial article that includes: an antimicrobial composite region that includes a matrix comprising a polymeric material, and a first plurality of particles within the matrix. The particles include a phase-separable glass with a copper-containing antimicrobial agent. The antimicrobial composite region can be a film containing the first plurality of particles that is subsequently laminated to a bulk element. The first plurality of particles can also be pressed into the film or a bulk element to define an antimicrobial composite region. An exposed surface portion of the antimicrobial composite region can exhibit at least a log 2 reduction in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, and Pseudomonas aeruginosa bacteria under a Modified EPA Copper Test Protocol.

Abstract: A device for delivery of a therapeutic agent to a surgical cavity, including: a porous, mucoadhesive, freeze-dried polymeric matrix having first and second opposed surfaces, the matrix formed by a composition including chitosan; a plurality of particles embedded within the matrix, the particles containing the therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan. The first surface of the matrix is configured to be applied to the surgical cavity; the device releases the particles through the first surface; the device is also sterilized and provides release of approximately 20% to 100% of the therapeutic agent within 20 minutes of application to the surgical cavity.

Abstract: The present invention relates to an oral dissolvable film (ODF) containing an active ingredient (e.g., vitamin D) that is, outside of the ODF, relatively unstable to at least one of heat, light, moisture, and oxygen. The present invention also relates to methods of manufacturing and using the same.

Abstract: A dispensable grease sealant includes a base component in an amount of 50 wt % or more, based on a total weight of the sealant, and a thickener. The base component is selected from a group including a silicone wax, a liquid rubber, and a combination thereof.

Abstract: A system that transdermally delivers a drug to a patient can be used to reduce suffering from acute/chronical musculoskeletal pain. The system includes a backing layer, an adhesive layer, a topical applicator, a suitable quantity of drug, and a quantity of topical carrier. The topical applicator is connected across and against the backing layer by the adhesive layer. The suitable quantity of drug and the quantity of topical carrier are homogenously mixed together as a topical medication, which is retained and dispensed from the topical applicator. The topical applicator includes a flat applicator body, a plurality of blunted spikes, and a containment rim. The flat applicator body is the structural base of the topical applicator. The containment rim is used to perimetrically confine the topical medication. The blunted spikes are used to increase the surface area of the topical applicator in order to improve its retention of the topical medication.

Abstract: A nitric oxide-releasing 3D printing ink is described for its composition and uses in fabricating a plurality of types of nitric oxide-releasing medical devices. The printing ink composition comprises a mixture of at least one nitric oxide donor and at least one polymer. The nitric oxide-releasing medical device is manufactured by 3D printing technology and provides antimicrobial and/or antithrombus effects by releasing nitric oxide in the presence of moisture.

Abstract: The present invention relates to polyoxazoline polymers, polymer combinations and compositions comprising those polymers or combinations of polymers. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: An antibacterial polymer and a preparation method thereof are provided. The antibacterial polymer is obtained by polymerization of a polyol and a guanidine salt, and has the following structure: In the preparation method, non-toxic and non-irritating polyols are used as raw materials, wherein the non-toxic and non-irritating polyols are friendly to an environment and a human body.

Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a polymer matrix and one or more flavorants and/or active ingredients embedded in the polymer matrix. The polymer matrix can include a copolymer of ethylene and one or more vinyl monomers or zein. For example, the polymer can be ethylene-vinyl acetate copolymer and/or ethylene-vinyl alcohol copolymer. In some cases, the oral product can include tobacco and/or nicotine.